2-(4-Piperazin-1-ylphenyl)propan-2-ol | 1095543-99-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-(4-Piperazin-1-ylphenyl)propan-2-ol
• CAS: 1095543-99-9
• 化学式: C₁₃H₂₀N₂O
• 分子量: 220.315
• InChiKey: PMUDQYWHTVSIIZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  35.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(4-Piperazin-1-ylphenyl)propan-2-ol 、 2-甲基-4-苯基-5-恶唑羧酸 在 N-甲基吗啉 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 、 正丁醇 为溶剂， 反应 1.0h， 生成 (4-(4-(2-hydroxypropan-2-yl)phenyl)piperazin-1-yl)(2-methyl-4-phenyloxazol-5-yl)methanone
  参考文献：
  名称：

  Synthesis and Biological Evaluation of Aryloxazole Derivatives as Antimitotic and Vascular-Disrupting Agents for Cancer Therapy

  摘要：

  A series of aryloxazole, thiazole, and isoxazole derivatives was synthesized as vascular-targeting anticancer agents. Antiproliferative activity and tumor vascular-disrupting activity of all of the synthesized compounds were tested in vitro using various human cancer cell lines and HUVECs (human umbilical vein endothelial cells). Several compounds with an arylpiperazinyl oxazole core showed excellent cytotoxicity and metabolic stability in vitro. Among this series, two representative compounds (6-48 and 6-51) were selected and tested for the evaluation of anticancer effects in vivo using tumor-bearing mice. Compound 6-48 effectively reduced tumor growth (42.3% reduction in size) at the dose of 100 mg/kg. We believe that compound 6-48 will serve as a good lead compound for antimitotic and vascular-disrupting agents; further investigation to improve the in vivo efficacy of this series is underway.

  DOI：

  10.1021/jm400840p

文献信息

• COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES
  申请人：Ashton Kate

  公开号：US20120225854A1

  公开（公告）日：2012-09-06

  The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts thereof, that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.

  本发明涉及公式I的化合物或其药学上可接受的盐，其与葡萄糖激酶调节蛋白相互作用。此外，本发明涉及使用这些化合物或其药学上可接受的盐以及含有这些化合物或其药学上可接受的盐的药物组合物治疗2型糖尿病以及其他与葡萄糖激酶调节蛋白有关的疾病和/或病况的方法。
• US8431563B2
  申请人：——

  公开号：US8431563B2

  公开（公告）日：2013-04-30
• Synthesis and Biological Evaluation of Aryloxazole Derivatives as Antimitotic and Vascular-Disrupting Agents for Cancer Therapy
  作者：Min Jeong Choi、Eun Sun No、Dhanaji Achyutrao Thorat、Jae Wan Jang、Hakkyun Yang、Jaeick Lee、Hyunah Choo、Soo Jin Kim、Chang Sik Lee、Soo Young Ko、Jiyoun Lee、GhilSoo Nam、Ae Nim Pae

  DOI：10.1021/jm400840p

  日期：2013.11.27

  A series of aryloxazole, thiazole, and isoxazole derivatives was synthesized as vascular-targeting anticancer agents. Antiproliferative activity and tumor vascular-disrupting activity of all of the synthesized compounds were tested in vitro using various human cancer cell lines and HUVECs (human umbilical vein endothelial cells). Several compounds with an arylpiperazinyl oxazole core showed excellent cytotoxicity and metabolic stability in vitro. Among this series, two representative compounds (6-48 and 6-51) were selected and tested for the evaluation of anticancer effects in vivo using tumor-bearing mice. Compound 6-48 effectively reduced tumor growth (42.3% reduction in size) at the dose of 100 mg/kg. We believe that compound 6-48 will serve as a good lead compound for antimitotic and vascular-disrupting agents; further investigation to improve the in vivo efficacy of this series is underway.